Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
NCT00327119 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2009-09-14
Summary
The primary objective of this study is to assess the effect of treatment with ABX-EGF on best overall objective response rate by modified RECIST (confirmed complete or partial response) in Japanese subjects with metastatic colorectal cancer.
Conditions
Interventions
- DRUG
-
ABX-EGF (panitumumab)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-04-30
More Related Trials
-
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
NCT00111774 ·Status: COMPLETED ·Phase: PHASE2
-
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
NCT00004879 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
NCT00113776 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
NCT00346099 ·Status: WITHDRAWN ·Phase: PHASE2
-
Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
NCT03311750 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer
NCT03017807 ·Status: COMPLETED ·Phase: PHASE1
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
NCT04117945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
NCT00819780 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
NCT05239650 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NCT00891930 ·Status: COMPLETED ·Phase: PHASE2
-
Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
NCT02437071 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
NCT03356158 ·Status: UNKNOWN ·Phase: PHASE1
-
Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR
NCT03940131 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
NCT02613221 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
NCT02211443 ·Status: UNKNOWN ·Phase: PHASE1
-
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
NCT04853043 ·Status: TERMINATED ·Phase: PHASE2
-
Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
NCT02497157 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
NCT01767857 ·Status: TERMINATED ·Phase: PHASE3
-
Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
NCT00842257 ·Status: COMPLETED ·Phase: PHASE2
-
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT04587128 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
NCT03087071 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.
NCT00531115 ·Status: TERMINATED ·Phase: PHASE2
-
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
NCT01412957 ·Status: COMPLETED ·Phase: PHASE3
-
Panitumumab Skin Toxicity Prevention Trial
NCT03167268 ·Status: UNKNOWN ·Phase: PHASE2
-
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
NCT00017082 ·Status: COMPLETED ·Phase: PHASE2